Menu
  • Join
  • Login
  • Contact
 

Search abstracts


In vitro release of novel dosage forms

  • At: 2011 FIP Congress in Hyderabad (India)
  • Type: Presentation
  • By: FRIEDEL, Horst-Dieter (Bayer Healthcare Pharmaceuticals, Berlin, Germany)
  • Co-author(s): Brown, CK (Eli Lilly and Company, Indianapolis, United States of America)
    Barker, AR (Eli Lilly and Company, Indianapolis, United States of America)
    Buhse, LF (Food and Drug Administration/CDER/OPS, St. Louis, United States of America)
    Keitel, S (EDQM, Strasbourg, France)
    Cecil, TL (United States Pharmacopoeia, Rockville, United States of America)
    Kraemer, J (PHAST, Homburg, Germany)
    Morris, JM (Irish Medicines Board, Dublin, Ireland)
    Reppas, C (National & Kapodistrian University of Athens, Panepistimiopolis, Greece)
    Stickelmeyer, MP (Eli Lilly and Company, Indianapolis, United States of America)
    Yomota, C (National Institute of Health Science, Tokyo, Japan)
    Shah, VP (FIP Scientific Secretary, The Hague, Netherlands)
  • Abstract:

    Although dissolution testing was initially developed for solid oral dosage forms, the application of dissolution testing has expanded to a variety of "novel" or "special" dosage forms. Analogous to the dissolution test for solid oral dosage forms the drug release test of novel dosage forms is used for the biopharmaceutical characterization of the

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses